A citation-based method for searching scientific literature

Rashi Yadav, William L Redmond. Curr Oncol Rep 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Imaging-Based Outcomes for 24 Gy in 2 Daily Fractions for Patients with de Novo Spinal Metastases Treated With Spine Stereotactic Body Radiation Therapy (SBRT).
Chia-Lin Tseng, Hany Soliman, Sten Myrehaug, Young K Lee, Mark Ruschin, Eshetu G Atenafu, Mikki Campbell, Pejman Maralani, Victor Yang, Albert Yee,[...]. Int J Radiat Oncol Biol Phys 2018
57
100

Anti-OX40 monoclonal antibody therapy in combination with radiotherapy results in therapeutic antitumor immunity to murine lung cancer.
Hiroshi Yokouchi, Koichi Yamazaki, Kenji Chamoto, Eiki Kikuchi, Naofumi Shinagawa, Satoshi Oizumi, Fumihiro Hommura, Takashi Nishimura, Masaharu Nishimura. Cancer Sci 2008
66
100


Induction of anti-mammary cancer immunity by engaging the OX-40 receptor in vivo.
A Morris, J T Vetto, T Ramstad, C J Funatake, E Choolun, C Entwisle, A D Weinberg. Breast Cancer Res Treat 2001
52
100

Batf3-dependent CD103+ dendritic cells are major producers of IL-12 that drive local Th1 immunity against Leishmania major infection in mice.
María Martínez-López, Salvador Iborra, Ruth Conde-Garrosa, David Sancho. Eur J Immunol 2015
100
100

Antibodies targeting human OX40 expand effector T cells and block inducible and natural regulatory T cell function.
Kui S Voo, Laura Bover, Megan L Harline, Long T Vien, Valeria Facchinetti, Kazuhiko Arima, Larry W Kwak, Yong J Liu. J Immunol 2013
65
100

Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial.
David A Palma, Robert Olson, Stephen Harrow, Stewart Gaede, Alexander V Louie, Cornelis Haasbeek, Liam Mulroy, Michael Lock, George B Rodrigues, Brian P Yaremko,[...]. Lancet 2019
799
100

The genomic landscape of breast cancer and its interaction with host immunity.
Stephen Luen, Balaji Virassamy, Peter Savas, Roberto Salgado, Sherene Loi. Breast 2016
128
100

48
100


Engagement of the OX-40 receptor in vivo enhances antitumor immunity.
A D Weinberg, M M Rivera, R Prell, A Morris, T Ramstad, J T Vetto, W J Urba, G Alvord, C Bunce, J Shields. J Immunol 2000
292
100

Immune response to firefly luciferase as a naked DNA.
Yong Hyun Jeon, Yun Choi, Joo Hyun Kang, Chul Woo Kim, Jae Min Jeong, Dong Soo Lee, June-Key Chung. Cancer Biol Ther 2007
26
100

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.
S Adams, S Loi, D Toppmeyer, D W Cescon, M De Laurentiis, R Nanda, E P Winer, H Mukai, K Tamura, A Armstrong,[...]. Ann Oncol 2019
257
100

DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity.
Claire Vanpouille-Box, Amandine Alard, Molykutty J Aryankalayil, Yasmeen Sarfraz, Julie M Diamond, Robert J Schneider, Giorgio Inghirami, C Norman Coleman, Silvia C Formenti, Sandra Demaria. Nat Commun 2017
779
100

IL-6: regulator of Treg/Th17 balance.
Akihiro Kimura, Tadamitsu Kishimoto. Eur J Immunol 2010
945
100

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy.
Spencer C Wei, Colm R Duffy, James P Allison. Cancer Discov 2018
100

Restoring function in exhausted CD8 T cells during chronic viral infection.
Daniel L Barber, E John Wherry, David Masopust, Baogong Zhu, James P Allison, Arlene H Sharpe, Gordon J Freeman, Rafi Ahmed. Nature 2006
100

OX40 is required for regulatory T cell-mediated control of colitis.
Thibault Griseri, Mark Asquith, Claire Thompson, Fiona Powrie. J Exp Med 2010
125
100

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study.
Luc Y Dirix, Istvan Takacs, Guy Jerusalem, Petros Nikolinakos, Hendrik-Tobias Arkenau, Andres Forero-Torres, Ralph Boccia, Marc E Lippman, Robert Somer, Martin Smakal,[...]. Breast Cancer Res Treat 2018
348
100

Batf3-dependent CD103(+) dendritic cell accumulation is dispensable for mucosal and systemic antifungal host defense.
Timothy J Break, Kevin W Hoffman, Muthulekha Swamydas, Chyi-Chia Richard Lee, Jean K Lim, Michail S Lionakis. Virulence 2016
13
100

Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.
S Loi, S Michiels, R Salgado, N Sirtaine, V Jose, D Fumagalli, P-L Kellokumpu-Lehtinen, P Bono, V Kataja, C Desmedt,[...]. Ann Oncol 2014
780
100

OX40 Costimulation Inhibits Foxp3 Expression and Treg Induction via BATF3-Dependent and Independent Mechanisms.
Xiaolong Zhang, Xiang Xiao, Peixiang Lan, Junhui Li, Yaling Dou, Wenhao Chen, Naoto Ishii, Shuqiu Chen, Bo Xia, Kaifu Chen,[...]. Cell Rep 2018
51
100

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
David J Messenheimer, Shawn M Jensen, Michael E Afentoulis, Keith W Wegmann, Zipei Feng, David J Friedman, Michael J Gough, Walter J Urba, Bernard A Fox. Clin Cancer Res 2017
170
100

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Peter Schmid, Sylvia Adams, Hope S Rugo, Andreas Schneeweiss, Carlos H Barrios, Hiroji Iwata, Véronique Diéras, Roberto Hegg, Seock-Ah Im, Gail Shaw Wright,[...]. N Engl J Med 2018
100


Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER Database.
Ki-Tae Hwang, Jongjin Kim, Jiwoong Jung, Ji Hyun Chang, Young Jun Chai, So Won Oh, Sohee Oh, Young A Kim, Sung Bae Park, Kyu Ri Hwang. Clin Cancer Res 2019
48
100

PI3Kαδ Inhibitor Combined With Radiation Enhances the Antitumor Immune Effect of Anti-PD1 in a Syngeneic Murine Triple-Negative Breast Cancer Model.
Won Ick Chang, Min Guk Han, Mi Hyun Kang, Ji Min Park, Eric Eunshik Kim, Junhyung Bae, Soyeon Ahn, In Ah Kim. Int J Radiat Oncol Biol Phys 2021
6
100

Molecular and cellular insights into T cell exhaustion.
E John Wherry, Makoto Kurachi. Nat Rev Immunol 2015
100

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.
Sherene Loi, Damien Drubay, Sylvia Adams, Giancarlo Pruneri, Prudence A Francis, Magali Lacroix-Triki, Heikki Joensuu, Maria Vittoria Dieci, Sunil Badve, Sandra Demaria,[...]. J Clin Oncol 2019
291
100

Stereotactic Radiotherapy Increases Functionally Suppressive Regulatory T Cells in the Tumor Microenvironment.
Yuki Muroyama, Thomas R Nirschl, Christina M Kochel, Zoila Lopez-Bujanda, Debebe Theodros, Wendy Mao, Maria A Carrera-Haro, Ali Ghasemzadeh, Ariel E Marciscano, Esteban Velarde,[...]. Cancer Immunol Res 2017
98
100

Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice.
Michael J Gough, Marka R Crittenden, MaryClare Sarff, Puiyi Pang, Steven K Seung, John T Vetto, Hong-Ming Hu, William L Redmond, John Holland, Andrew D Weinberg. J Immunother 2010
111
100

A Combination of Radiotherapy, Hyperthermia, and Immunotherapy Inhibits Pancreatic Tumor Growth and Prolongs the Survival of Mice.
Javed Mahmood, Allen A Alexander, Santanu Samanta, Shriya Kamlapurkar, Prerna Singh, Ali Saeed, France Carrier, Xuefang Cao, Hem D Shukla, Zeljko Vujaskovic. Cancers (Basel) 2020
8
100

Inhibition of PI4K IIIα radiosensitizes in human tumor xenograft and immune-competent syngeneic murine tumor model.
Younghee Park, Ji Min Park, Dan Hyo Kim, Jeanny Kwon, In Ah Kim. Oncotarget 2017
11
100

Pembrolizumab for Early Triple-Negative Breast Cancer.
Peter Schmid, Javier Cortes, Lajos Pusztai, Heather McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck,[...]. N Engl J Med 2020
605
100

Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman. Nat Rev Drug Discov 2015
761
100

Radiotherapy and immunotherapy: a beneficial liaison?
Ralph R Weichselbaum, Hua Liang, Liufu Deng, Yang-Xin Fu. Nat Rev Clin Oncol 2017
482
100

Immunomodulatory Effects of Stereotactic Body Radiation Therapy: Preclinical Insights and Clinical Opportunities.
Ariel E Marciscano, Adriana Haimovitz-Friedman, Percy Lee, Phuoc T Tran, Wolfgang A Tomé, Chandan Guha, Feng-Ming Spring Kong, Arjun Sahgal, Issam El Naqa, Andreas Rimner,[...]. Int J Radiat Oncol Biol Phys 2021
32
100

Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells.
Guohe Lin, Jin Wang, Xiangming Lao, Jun Wang, Lian Li, Shuhong Li, Jinye Zhang, Yong Dong, Alfred E Chang, Qiao Li,[...]. J Immunother 2012
50
100


Immunotherapy for Breast Cancer: What Are We Missing?
Robert H Vonderheide, Susan M Domchek, Amy S Clark. Clin Cancer Res 2017
121
100

Science gone translational: the OX40 agonist story.
Andrew D Weinberg, Nicholas P Morris, Magdalena Kovacsovics-Bankowski, Walter J Urba, Brendan D Curti. Immunol Rev 2011
101
100

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.
Javier Cortes, David W Cescon, Hope S Rugo, Zbigniew Nowecki, Seock-Ah Im, Mastura Md Yusof, Carlos Gallardo, Oleg Lipatov, Carlos H Barrios, Esther Holgado,[...]. Lancet 2020
343
100

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.
Sathana Dushyanthen, Zhi Ling Teo, Franco Caramia, Peter Savas, Christopher P Mintoff, Balaji Virassamy, Melissa A Henderson, Stephen J Luen, Mariam Mansour, Michael H Kershaw,[...]. Nat Commun 2017
58
100

PD-L1 expression in triple-negative breast cancer.
Elizabeth A Mittendorf, Anne V Philips, Funda Meric-Bernstam, Na Qiao, Yun Wu, Susan Harrington, Xiaoping Su, Ying Wang, Ana M Gonzalez-Angulo, Argun Akcakanat,[...]. Cancer Immunol Res 2014
685
100

Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Sharareh Niknam, Hampartsoum B Barsoumian, Jonathan E Schoenhals, Heather L Jackson, Niranjan Yanamandra, Mauricio S Caetano, Ailin Li, Ahmed I Younes, Alexandra Cadena, Taylor R Cushman,[...]. Clin Cancer Res 2018
33
100

TREX1 dictates the immune fate of irradiated cancer cells.
Claire Vanpouille-Box, Silvia C Formenti, Sandra Demaria. Oncoimmunology 2017
56
100

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy.
Carsten Denkert, Gunter von Minckwitz, Silvia Darb-Esfahani, Bianca Lederer, Barbara I Heppner, Karsten E Weber, Jan Budczies, Jens Huober, Frederick Klauschen, Jenny Furlanetto,[...]. Lancet Oncol 2018
733
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.